Gao‐Jun Teng

A Dynamic Prognostic and Adaptive Treatment Framework for Advanced Biliary Tract Cancer

Jiakun Mei, Xue Han⊗, Kai Zhang, Naijian Ge et autres

BACKGROUND & AIMS: First-line immuno-chemotherapy is standard for advanced biliary tract cancer (BTC), but outcomes vary substantially, necessitating longitudinal monitoring and treatment adaptation. We aimed to develop models that dynamically update survival predictions using evolving clinical data to support real-time prognostic stratification. …

cn (code pays fourni par la source)

Machine Learning–Guided Personalized Immunochemotherapy Strategies in Intrahepatic Cholangiocarcinoma

Jiakun Mei, Kai Zhang, Ying Zhang, Zhen Li et autres

BACKGROUND & AIMS: Immunochemotherapy (IO-chemo) has become standard care for patients with unresectable intrahepatic cholangiocarcinoma (iCCA), but benefit of adding IO varies greatly among individuals. We sought to develop a system to identify patients most likely to benefit from this treatment based …

cn (code pays fourni par la source)

Reply to: Different Stage But Similar Survival in Hepatocellular Carcinoma: A Dilemma of Treatment Timing?

Zhi‐Cheng Jin, Bin‐Yan Zhong, Hai‐Dong Zhu, Gao‐Jun Teng

cn (code pays fourni par la source)

Ultrasound-guided cryoablation for breast cancer ineligible for or refused surgery: a single-center experience

Yuanyuan Ye, Qi Zhang, Chu Hui Zeng, Hai‐Dong Zhu et autres

cn (code pays fourni par la source)

626 Real-time multidimensional prognostic model for immuno-chemotherapy in advanced biliary tract cancer: an observational multicohort study

Junhao Mei, Xue Han⊗, Kai Zhang, Rong Liu et autres

Background The standard of care first-line treatment for advanced biliary tract cancer (BTC) has been updated to immune checkpoint inhibitors combined with chemotherapy. However, immuno-chemotherapy for BTC still demonstrates significant population heterogeneity, requiring continuous prognostic monitoring and dynamic treatment modifications tailored to …

cn (code pays fourni par la source)

Current status and future prospects of interventional radiology in China

Xiaowen Song, Hai‐Dong Zhu, Gao‐Jun Teng

The phrase “interventional radiology” (IR) was first coined by Margulis in 1967,[1] defining an emerging discipline that leverages image-guided modalities for the diagnosis and management of space-occupying lesions (such as tumors) and vascular pathologies (such as thrombosis and atherosclerosis). Since its establishment …

cn (code pays fourni par la source)

2523eP Preclinical pharmacokinetic and pharmacodynamic study of GS24-B039, a 3-month long-acting abiraterone prodrug

Yujie Zhang, Y. Chen, Gao‐Jun Teng, Ge Gao et autres

cn (code pays fourni par la source)

Thermosensitive nanogel: An embolic agent for durable and conformal embolization in transarterial chemoembolization of hepatocellular carcinoma

Rong Ding, Han Li, Ming Huang, Yanbing Zhao et autres

Embolic agents play a vital role in transarterial chemoembolization (TACE), and continuous advancements in embolic materials have significantly improved clinical outcomes. Embogel, a thermosensitive embolic agent, undergoes a temperature-induced phase transition from a liquid gel ex vivo to a solid gel upon …

cn, hk (code pays fourni par la source)

Interventional management of pancreatic cancer: Current strategies and future horizons

Yuchen Wang, Rong Yan, Jian Guo Lu, Gao‐Jun Teng

Abstract Pancreatic cancer is a highly lethal malignancy characterized by rapid progression and increasing global incidence and mortality rates. Although surgery remains the only potentially curative treatment, most patients are ineligible for surgical intervention at diagnosis. For those with unresectable pancreatic cancer, …

cn (code pays fourni par la source)

Precision transarterial chemoembolization in hepatocellular carcinoma: patient selection, standardized techniques, and quantitative evaluation

Bin‐Yan Zhong, Zhongzhi Jia, Ho-Young Song, Wen Zhang et autres

Transarterial chemoembolization (TACE) plays a critical role in the treatment of hepatocellular carcinoma (HCC), yet variability in its performance leads to inconsistent prognostic outcomes, with objective response rates (ORRs) ranging from below 10% to over 60% for intermediate HCC. Published evidence and …

cn, kr, us, gb, my (code pays fourni par la source)

Combination locoregional and systemic therapies in hepatocellular carcinoma

Bin‐Yan Zhong, Wenzhe Fan, Justin J. Guan, Zhenwei Peng et autres

cn, us, bd (code pays fourni par la source)

Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study

Bruno Sangro, Joseph Patrick Erinjeri, Shukui Qin, Stephen Lam Chan et autres

es, jp, us, cn, hk, kr, vn, th, fr, tw, br, au, pl, it (code pays fourni par la source)